ClinicalTrials.gg

Staphylococcal Skin Infections clinical trials

What moves in its pipeline, every Monday. Free with an account during the beta.

The registry lists 30 studies for Staphylococcal Skin Infections across more than 10 countries. 0 are recruiting or about to start. 24 of them are mainly about Staphylococcal Skin Infections (how this is decided). Per ClinicalTrials.gov, last updated 2025-07-17. Counting its narrower condition Impetigo too: 60 studies, 3 open.

Status

Completed
27
Terminated
2
Status unknown
1

Phase

Phase 3
7
Phase 1
6
Phase 4
5
Phase 2
5

Where

United States
20
Ukraine
4
Romania
3
Mexico
3
Argentina
3
Poland
3

Who develops what

Add Staphylococcal Skin Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 0 programs from 0 companies, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
VancomycinEarlier only
Evidence
  • NCT02814916 · AbbVie · Phase 3 · comparator · “Vancomycin” · registered Jun 2016
  • NCT01419184 · Merck & Co., Inc · Phase 4 · comparator · “Vancomycin” · registered Aug 2011
  • NCT00442832 · Zymeworks · Phase 2 · comparator · “Vancomycin” · registered Feb 2007
  • NCT00423657 · AbbVie · Phase 3 · comparator · “vancomycin plus aztreonam” · registered Jan 2007
  • NCT00424190 · AbbVie · Phase 3 · comparator · “IV Vancomycin plus IV Aztreonam” · registered Jan 2007
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed00 studies
LinezolidEarlier only
Evidence
  • NCT00948142 · Arrevus Inc. · Phase 2 · comparator · “Linezolid” · registered Jul 2009
  • NCT00646958 · CorMedix Therapeutics · Phase 2 · comparator · “Linezolid” · registered Mar 2008
Pfizer78% of its industry studiesUS: off-patent, 16 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 0 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Staphylococcal Skin Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Who these studies take

No Staphylococcal Skin Infections study is recruiting now.

Across all 30 studies, recruiting or not: 40% stop at 75 or younger and 37% at 65; 23% take children; 0% are for women only and 7% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 30 of 30. search them.